| 2 | 1/1 | 返回列表 |
| 查看: 282 | 回復(fù): 1 | |||
myIDname木蟲 (著名寫手)
人民大會堂首席清潔工
|
[交流]
2012/11/30 news of the week@SCIENCE 之六:神經(jīng)學(xué)專家卷入內(nèi)部交易案件
|
|
本周第六條報導(dǎo),原文鏈接:http://www.sciencemag.org/content/338/6111/1132.1.full.pdf New York 6 Neurologist Implicated In Insider Trading Case 神經(jīng)學(xué)專家卷入內(nèi)部交易案件 Federal authorities filed charges last week in what they said is the most lucrative insider trading case in history. According to the Securities and Exchange Commission (SEC), Sidney Gilman, a neurology professor at the University of Michigan, Ann Arbor, fed secret information about clinical trials of an Alzheimer’s drug to Mathew Martoma, a formerportfolio manager at a division of the hedge fund SAC Capital Advisors, allowing Martoma to make more than $276 million inillicit profits and avoid losses with well-timed stock purchases and sales. 聯(lián)邦政府上周發(fā)出了一份指控,里面涉及了到史上涉案金額最高的內(nèi)部交易。根據(jù)安全交易委員會(SEC)提供的信息,Ann Arbor密西根大學(xué)的神經(jīng)學(xué)教授Sidney Gilman向Mathew Martoma泄露了Alzheimer公司一種藥物的臨床試驗機密信息,使得這位SCA咨詢公司的前任對沖基金部負責人Martoma通過把握買賣股票的有利時機避免了損失,同時獲取了超過2.76億美元的非法收入。 The drug, bapineuzumab, was a oncepromising Alzheimer’s therapy originally developed by Elan and Wyeth. Based on information from Gilman, Martoma allegedly invested more than $700 million in the companies’ stocks when the prospects for bapineuzumab looked good, and later unloaded more than $960 million worth of stock in just over a week when the news turned bad. Bapineuzumab是Alzheimer公司的治療藥物,最初由Elan和Wyeth研發(fā),并曾被一度看好。根據(jù)Gilman交待的情況,Martoma涉嫌在bapineuzumab市場前景光明的時候購買了7億多美元公司股票,而后僅僅在一個星期之后,當情況逆轉(zhuǎn)的時候又拋出了價值超過9.6億美元的公司股票。 SEC alleges that Gilman, a former chair of the Michigan neurology department who served as chair of the trial’s Safety and Monitoring Committee, received nearly $108,000 for his consultations with Martoma from a New York–based firm that connects investors with technical experts. Gilman is cooperating with authorities in exchange for nonprosecution. Gilman之前擔任密西根大學(xué)神經(jīng)學(xué)系系主任,現(xiàn)在是臨床試驗安全監(jiān)管委員會主席。SEC指控他通過紐約一家聯(lián)系投資人和技術(shù)專家的公司,收取了Martoma將近10.8萬美元的咨詢費。為了免于被起訴,Gilman目前正在配合政府調(diào)查。 *************************************************************** Science的原文和本翻譯僅用于網(wǎng)友交流學(xué)習之用,若您有其它用途,比如商業(yè)用途等,請聯(lián)系Science雜志社了解原文使用權(quán)等相關(guān)事宜。謝謝! |

木蟲 (著名寫手)
人民大會堂首席清潔工

| 2 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研]
|
孅華 2026-03-22 | 5/250 |
|
|---|---|---|---|---|
|
[考研] 【考研調(diào)劑】化學(xué)專業(yè) 281分,一志愿四川大學(xué),誠心求調(diào)劑 +12 | 吃吃吃才有意義 2026-03-19 | 13/650 |
|
|
[考研] 269求調(diào)劑 +4 | 我想讀研11 2026-03-23 | 4/200 |
|
|
[考研] 291 求調(diào)劑 +4 | 化工2026屆畢業(yè)?/a> 2026-03-21 | 5/250 |
|
|
[考研] 0854電子信息求調(diào)劑 324 +3 | Promise-jyl 2026-03-23 | 3/150 |
|
|
[考研] 333求調(diào)劑 +6 | 87639 2026-03-21 | 10/500 |
|
|
[考研] 一志愿西安交通大學(xué)材料工程專業(yè) 282分求調(diào)劑 +11 | 楓橋ZL 2026-03-18 | 13/650 |
|
|
[基金申請] 山東省面上項目限額評審 +4 | 石瑞0426 2026-03-19 | 4/200 |
|
|
[考研] 286求調(diào)劑 +10 | Faune 2026-03-21 | 10/500 |
|
|
[考研] 初試 317 +7 | 半拉月丙 2026-03-20 | 7/350 |
|
|
[考研] 301求調(diào)劑 +10 | yy要上岸呀 2026-03-17 | 10/500 |
|
|
[考研] 274求調(diào)劑 +10 | S.H1 2026-03-18 | 10/500 |
|
|
[考研] 一志愿中海洋材料工程專碩330分求調(diào)劑 +8 | 小材化本科 2026-03-18 | 8/400 |
|
|
[考研] 考研調(diào)劑求學(xué)校推薦 +3 | 伯樂29 2026-03-18 | 5/250 |
|
|
[考研]
|
然11 2026-03-19 | 4/200 |
|
|
[考研] 329求調(diào)劑 +9 | 想上學(xué)吖吖 2026-03-19 | 9/450 |
|
|
[考研] 295材料求調(diào)劑,一志愿武漢理工085601專碩 +5 | Charlieyq 2026-03-19 | 5/250 |
|
|
[考研] 085410人工智能專碩317求調(diào)劑(0854都可以) +4 | xbxudjdn 2026-03-18 | 4/200 |
|
|
[考研] 【同濟軟件】軟件(085405)考研求調(diào)劑 +3 | 2026eternal 2026-03-18 | 3/150 |
|
|
[考研] 收復(fù)試調(diào)劑生 +4 | 雨后秋荷 2026-03-18 | 4/200 |
|